Autres langues Merrimack Pharmaceuticals, Inc.

Actions

MACK

US5903282094

Temps réel estimé Cboe BZX Autres places de cotation 20:14:38 17/05/2024			Varia. 5j.	Varia. 1 janv.
15,14 ^USD	+0,10 %		+0,17 %	+12,94 %

15/05	Merrimack Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
27/03	Merrimack reçoit un paiement d'étape de 225 millions de dollars et convoque une assemblée pour un plan de dissolution	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock	13/05
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock	10/05
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution	09/05
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024	09/05
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	30/04
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	27/03
Merrimack Receives $225 Million Milestone Payment from Ipsen	27/03
Merrimack Reports Full Year 2023 Financial Results	07/03
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	14/02
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	14/02
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	13/02
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	13/02
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	16/11
Merrimack Reports Third Quarter 2023 Financial Results	02/11
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index	18/09/23
Insider Buy: Merrimack Pharmaceuticals	09/08/23
Merrimack Reports Second Quarter 2023 Financial Results	03/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Merrimack Pharmaceuticals, Inc.

Actions

MACK

US5903282094

Autres langues

Filtres